Clinical Trial

The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The hypothesis for this study is that oral Semaglutide, a GLP-1Ra, has a positive effect on the balance between build-up and degradation as well as the strength of the bones in men and women aged 50-85 years with type 2 diabetes and an increased risk of bone fractures. Treatment involves once daily oral GLP-1Ra semaglutide or matching placebo for 52 weeks. The effect will be measured by bone markers in blood samples, bone scans, bone tissue and bone marrow tests (bone marrow aspiration and biopsy), physical activity assessed by a questionnaire, and direct bone strength measured by microindentation at the start and end of the study.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-21; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2026-02-05
Status change: Not Yet Recruiting → Recruiting 2024-06-06
Trial Details
NCT Number NCT06050577
Lead Sponsor Odense University Hospital
Conditions Type 2 Diabetes, Osteopenia
Enrollment 64 participants
Start Date 2024-06-07
Primary Completion 2026-01-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-09